Invivyd, Inc.
NASDAQ:IVVDBiotechnology
+$0.04 today
- Market cap
- $138.68M
- Beta
- 0.63
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$0.25
Volume 6.71M
Average 3.62M
IVVD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Invivyd, Inc.NASDAQ: IVVD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$40.89M, compared with -$15.55M a year earlier. Trailing-twelve-month EBITDA was -$75.72M.
Context
- EBITDA amounted to 94.3% of revenue in FY2025, down 562.9 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$84.14M (-67.0%) for the fiscal year ending Dec 2026, a slowdown from the +69.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$40.89M-284.5% QoQ
- Last fiscal yearDec 2025
- -$50.38M+69.8% YoY
- LTMMar 2026
- -$75.72M+45.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -162.9% | -138.4% | +24.5 pp |
| 1 year | +69.8% | -67.0% | -136.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (50.38M) USD
- Year-over-year change
- +69.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (50.38M) | +69.8% |
| FY2024 | 2024-12-31 | (166.81M) | +18.9% |
| FY2023 | 2023-12-31 | (205.76M) | +8.9% |
| FY2022 | 2022-12-31 | (225.8M) | -2.9% |
| FY2021 | 2021-12-31 | (219.41M) | — |
EBITDA vs competitors
How IVVD compares with its peers on the latest reported figures
- IVVD's LTM Mar 2026 EBITDA of -$75.72M is the 8th highest of the 10 companies compared; the peer median is -$45.4M.
- Its year-over-year change of +45.7% is the 2nd highest of 9, against a peer median of +7.9%.
- EBITDA amounts to 135.5% of revenue for IVVD, versus a peer median of 224.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$22.06M | +62.9% | — | 28.2% | |
| LTM Mar 2026 | -$33.82M | +24.4% | — | 117.0% | |
| LTM Mar 2026 | -$35.22M | — | — | — | |
| LTM Sep 2026 | -$35.76M | -89.6% | — | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$45.4M | +19.5% | — | 2329.5% |
| LTM Mar 2026 | -$52.72M | +20.1% | — | 161.1% | |
| LTM Mar 2026 | -$62.94M | -39.6% | — | — | |
| LTM Mar 2026 | -$75.72M | +45.7% | — | 135.5% | |
| LTM Mar 2026 | -$100.38M | -3.7% | — | 287.9% | |
| LTM Mar 2026 | -$117.46M | -66.2% | — | 339.9% | |
| Peer median (excluding IVVD) | -$45.4M | +7.9% | — | 224.5% | |
Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 25.38M | 53.43M |
| Cost of Revenue | 0 | 0 | 0 | 1.62M | 3.75M |
| Gross Profit | 0 | 0 | 0 | 23.77M | 49.68M |
| Gross Margin | — | — | — | 93.6% | 93.0% |
| Research & Development | 182.89M | 179.21M | 158.66M | 137.25M | 38.31M |
| Selling, General & Admin | 36.52M | 47.04M | 49.13M | 63.39M | 66.93M |
| Operating Expenses | 226.91M | 248.03M | 212.76M | 200.64M | 105.24M |
| Depreciation & Amortization | 1K | 462K | 2.03M | 3.11M | 2.11M |
| EBITDA | (219.41M) | (225.8M) | (205.76M) | (166.81M) | (50.38M) |
| EBITDA Margin | — | — | — | -657.2% | -94.3% |
| Operating Income | (226.91M) | (248.03M) | (212.76M) | (176.88M) | (55.56M) |
| Operating Margin | — | — | — | -696.8% | -104.0% |
| Interest Income | 0 | 6.71M | 0 | 6.95M | 0 |
| Interest Expense | 0 | 43.08M | 0 | 0 | 0 |
| Other Income / Expenses | 118K | 6.71M | 14.12M | 6.95M | 3.07M |
| Income Before Tax | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Pre-Tax Margin | — | — | — | -669.4% | -98.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Net Margin | — | — | — | -669.4% | -98.2% |
| EPS (Basic) | (2.11) | (2.17) | (1.81) | (1.43) | (0.30) |
| EPS (Diluted) | (2.11) | (2.17) | (1.81) | (1.43) | (0.30) |
| Weighted Avg Shares | 110.78M | 108.27M | 109.53M | 118.56M | 172.21M |
| Weighted Avg Shares (Diluted) | 110.78M | 108.27M | 109.53M | 118.56M | 172.21M |
Invivyd, Inc.
NASDAQ:IVVD
Intrinsic Alpha fair value
Locked
Current Price
$0.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.